scispace - formally typeset
D

David B. Hoyt

Researcher at American College of Surgeons

Publications -  459
Citations -  33736

David B. Hoyt is an academic researcher from American College of Surgeons. The author has contributed to research in topics: Poison control & Injury Severity Score. The author has an hindex of 95, co-authored 455 publications receiving 31309 citations. Previous affiliations of David B. Hoyt include University of California, Berkeley & Naval Medical Center San Diego.

Papers
More filters
Journal ArticleDOI

Transfusion of plasma, platelets, and red blood cells in a 1: 1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: The PROPPR randomized clinical trial

TL;DR: In this article, the effectiveness and safety of transfusing patients with severe trauma and major bleeding using plasma, platelets, and red blood cells in a 1:1:1 ratio compared with a 1 :1:2 ratio was evaluated.
Journal ArticleDOI

Damage control resuscitation: Directly addressing the early coagulopathy of trauma

TL;DR: Reports of lactated Ringer s solution and normal saline increasing reperfusion injury and leukocyte adhesion lead one to conclude that the standard crystalloid based resuscitation guidelines in pre hospital trauma life support (PHTLS) and advanced traumaLife support (ATLS) may worsen the presenting acidosis and coagulopathy in severely injured trauma patients, and possibly increase ARDS, SIRS, and MOF.
Journal ArticleDOI

Prospective study of blunt aortic injury: Multicenter trial of the American Association for the Surgery of Trauma

Timothy C. Fabian, +50 more
TL;DR: Although newer diagnostic techniques are being applied, at this time aortography remains the diagnostic standard; bypass techniques, which provide distal aortic perfusion, produced significantly lower paraplegia rates than the clamp and sew approach.
Journal ArticleDOI

Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial.

TL;DR: Early enteral feeding of the experimental formula was safe and well tolerated in ICU patients and a substantial reduction in hospital length of stay was observed, along with a significant reduction in the frequency of acquired infections.